People with Diabetes Type 2 often require medication to control their blood sugar. During the 94th Endocrine Society Meeting data was presented from a study that took place at the Cleveland Clinic. Patients on Glipizide, Glyburide, and Glimepiride were shown to have a higher overall mortality rate than those on Metformin. Among the group of patients with heart disease, who were followed for 2.2 years, Glipizide, was associated with a 41% increased risk for mortality and glyburide was associated with a 38% greater risk for death. Glimepiride did not show an increased mortality rate among this group. As summarized and reported in Medscape, the authors recommended that metformin be used first, and if a sulfonylurea is needed, the health care provider should recognize that not all sulfonylureas are created equal.
MEDICAL ADVICE DISCLAIMER: The information included on this site is for educational purposes only. It is not intended nor implied to be a substitute for professional medical advice. The reader should always consult his or her health care provider to determine the appropriateness of the information for their own situation, or if they have any questions regarding a medical condition or treatment plan. Reading the information on this website does not create a physician-patient relationship.
